Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) traded down 5.3% on Thursday . The company traded as low as $10.50 and last traded at $11.12, with a volume of 412,981 shares. The stock had previously closed at $11.74.

A number of equities research analysts have recently weighed in on the company. Goldman Sachs Group Inc. assumed coverage on Momenta Pharmaceuticals in a research note on Monday, June 6th. They set a “neutral” rating and a $14.00 price target on the stock. Zacks Investment Research raised Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, April 27th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Momenta Pharmaceuticals in a report on Wednesday, May 4th. Brean Capital reaffirmed a “buy” rating and set a $19.00 target price on shares of Momenta Pharmaceuticals in a report on Wednesday, May 4th. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $18.00 target price (down previously from $21.00) on shares of Momenta Pharmaceuticals in a report on Wednesday, May 4th. Five research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $17.80.

The company’s market capitalization is $853.73 million. The stock’s 50-day moving average price is $11.16 and its 200 day moving average price is $10.47.

Momenta Pharmaceuticals (NASDAQ:MNTA) last issued its quarterly earnings data on Thursday, August 4th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.01. The business earned $26.40 million during the quarter, compared to the consensus estimate of $23.55 million. During the same period last year, the company earned ($0.04) earnings per share. The business’s quarterly revenue was down 41.2% compared to the same quarter last year. On average, analysts predict that Momenta Pharmaceuticals Inc. will post ($1.31) EPS for the current fiscal year.

In related news, President Craig A. Wheeler sold 5,880 shares of the stock in a transaction that occurred on Friday, May 20th. The stock was sold at an average price of $10.18, for a total value of $59,858.40. Following the completion of the transaction, the president now directly owns 349,521 shares of the company’s stock, valued at approximately $3,558,123.78. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

A number of institutional investors have modified their holdings of MNTA. Principal Financial Group Inc. raised its position in shares of Momenta Pharmaceuticals by 4.6% in the fourth quarter. Principal Financial Group Inc. now owns 423,158 shares of the biotechnology company’s stock worth $6,279,000 after buying an additional 18,504 shares during the period. Morgan Stanley raised its position in shares of Momenta Pharmaceuticals by 123.0% in the fourth quarter. Morgan Stanley now owns 69,759 shares of the biotechnology company’s stock worth $1,035,000 after buying an additional 38,470 shares during the period. GSA Capital Partners LLP raised its position in shares of Momenta Pharmaceuticals by 298.9% in the fourth quarter. GSA Capital Partners LLP now owns 88,251 shares of the biotechnology company’s stock worth $1,310,000 after buying an additional 66,130 shares during the period. New York State Common Retirement Fund raised its position in shares of Momenta Pharmaceuticals by 2.0% in the fourth quarter. New York State Common Retirement Fund now owns 150,991 shares of the biotechnology company’s stock worth $2,241,000 after buying an additional 2,900 shares during the period. Finally, California Public Employees Retirement System raised its position in shares of Momenta Pharmaceuticals by 2.9% in the fourth quarter. California Public Employees Retirement System now owns 200,600 shares of the biotechnology company’s stock worth $2,977,000 after buying an additional 5,600 shares during the period.

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. It focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics. It has developed generic version of Lovenox (enoxaparin sodium injection).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.